首页> 外文期刊>Emerging Infectious Diseases >An Outbreak of Hemoytic Uremic Syndrome Associated with Antibiotic Treatment of Hospital Inpatients for Dysentery
【24h】

An Outbreak of Hemoytic Uremic Syndrome Associated with Antibiotic Treatment of Hospital Inpatients for Dysentery

机译:溶血性尿毒综合症爆发与痢疾住院患者的抗生素治疗相关

获取原文
获取外文期刊封面目录资料

摘要

Shiga toxin (ST) from Shigella dysenteriae type 1 is accepted as a cause of hemolytic uremic syndrome (HUS); however, the reasons why HUS develops in only some infected patients are not clear (1). The possibility that antibiotic therapy is associated with the development of HUS has been explored for S. dysenteriae type 1 and for Escherichia coli O157:H7 (2–4). In May 1993, during an outbreak of S. dysenteriae type 1 in Gizan, Saudi Arabia, an association between antibiotic treatment and HUS was also observed (5). The strain of S. dysenteriae type 1 was resistant to ampicillin, tetracycline, chloramphenicol, and trimethoprim-sulfamethoxazole (TMP-SMX) and sensitive to nalidixic acid. We report here some of our preliminary observations for a concurrent outbreak.
机译:痢疾志贺氏菌1型的志贺毒素(ST)被认为是溶血性尿毒症综合征(HUS)的病因;但是,尚不清楚仅在部分感染患者中发生HUS的原因(1)。对于痢疾链球菌1型和大肠杆菌O157:H7(2-4),已经探讨了抗生素治疗与HUS发生有关的可能性。 1993年5月,在沙特阿拉伯吉赞爆发1型痢疾链球菌的过程中,还观察到抗生素治疗与HUS之间的关联(5)。 1型痢疾链球菌菌株对氨苄西林,四环素,氯霉素和甲氧苄氨磺胺甲基异恶唑(TMP-SMX)耐药,并对萘啶酸敏感。我们在这里报告了一些关于并发爆发的初步观察结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号